What is LumaCyte?
LumaCyte, Inc. operates at the intersection of microfluidics and advanced data analytics, providing a revolutionary label-free, single cell analysis and sorting platform. By leveraging its proprietary Laser Force Cytology (LFC) technology, the company enables researchers to measure intrinsic cellular properties without the need for traditional antibody or genetic labeling. This approach significantly reduces the complexity and cost associated with cellular analysis. The platform's ability to generate multivariate data sets facilitates the integration of Big Data strategies and cloud computing, providing deep insights into complex biological systems. Key applications for this technology span critical areas including viral infectivity for vaccine development, CAR T-cell immunotherapy, cancer biology research, and quality control within the biomanufacturing sector. By eliminating the reliance on exogenous labels, LumaCyte provides a more accurate and efficient workflow for drug discovery and process optimization.
How much funding has LumaCyte raised?
LumaCyte has raised a total of $327K across 2 funding rounds:
Debt
$150K
Debt
$177K
Debt (2020): $150K with participation from PPP
Debt (2021): $177K led by PPP
Key Investors in LumaCyte
PPP
Public-Private Partnership
What's next for LumaCyte?
With the recent influx of capital, LumaCyte is well-positioned to accelerate its commercialization efforts and deepen its penetration into the biomanufacturing and cell therapy markets. The strategic focus will likely shift toward expanding the adoption of its LFC platform in high-growth areas such as adventitious agent testing and large-scale vaccine production. As the company matures, the integration of advanced analytics and cloud-based diagnostic tools will remain a central pillar of its growth strategy. By continuing to refine its instrumentation, LumaCyte aims to set new industry standards for precision and efficiency in cellular analysis, ultimately driving innovation in pre-clinical drug discovery and therapeutic development.
See full LumaCyte company page
